$201B

Projected GLP‑1 market by 2030, up from $70B in 2025

6,500+

Independent pharmacies in the planned distribution network

150+

Peer reviewed studies on MANF, the TolloBio drug candidate

3

Operating subsidiaries: TolloMeds, TolloCare, TolloBio

The Problem

The world’s biggest weight‑loss drugs have a muscle problem

GLP‑1 agonists such as semaglutide and tirzepatide are reshaping obesity care. But an increased share of the weight patients lose is lean muscle mass when compared with traditional weight loss strategies.

Losing too much muscle while losing weight undermines metabolic health, strength and long term outcomes, particularly in older adults. Physicians increasingly need something they can put alongside the prescription, and there is no established standard of care for it.

Tollo Health’s answer is Forzet, a medical food intended for the dietary management of muscle loss associated with weight loss therapies, for use under physician supervision.

Preserving lean mass during weight loss

The Portfolio

Real Products. Real Problems Solved.

TolloMeds, LLC is the nutraceuticals division of Tollo Health that manufactures the medical foods and supplements in the Company’s portfolio. TolloCare, LLC is the healthcare delivery division of Tollo Health and runs the consumer “Health Lives Here” app that includes the telemedicine layer. TolloBio, LLC incubates the FDA‑regulated biopharmaceutical drug pipeline that will ultimately complement the Company’s nutraceutical portfolio.

Forzet™

Launching

A medical food for the dietary management of muscle loss associated with weight loss therapies, to be used under physician supervision.

Classification: Medical food · Launch timed with rollout of Health Lives Here targeted for September 2026

Galectovid™

Selling

A medical food that targets Galectin 1 and Galectin 3, proteins certain viruses use to enter cells and blunt the host immune response. Commercially available today.

Classification: Medical food · Launched 2025 with no marketing spend to date

Tollovid®

Selling

A botanically derived 3CL protease inhibitor dietary supplement for immune support, with a focus on long COVID. Licensed from NLC Viral Defense and back on the market since December 2025.

Classification: Dietary supplement · Re‑launched in 2025 with no marketing spend to date

Galectovid (MCAS)

Formulated, launch pending commercial manufacturing

A medical food that targets Galectin‑1 and Galectin‑3, proteins certain viruses use to enter cells and blunt the host immune response, formulated for patients with significant food sensitivities associated with Mast Cell Activation Syndrome (MCAS).

Classification: Medical food · Not yet marketed

ChondrovidMedical food

Chondrovid

Formulated, launch pending commercial manufacturing

A medical food that provides the body with essential amino acids in a ratio optimized to support mitochondrial biogenesis, for the dietary management of patients with low energy due to chronic infections.

Classification: Medical food · Not yet marketed

TolloglutideTolloBio

Tolloglutide (TolloBio)

Pre‑clinical following 505(b)2 pathway

A liquid formulation of the Company’s proprietary Forzet medical food combined with an undisclosed generic GLP‑1 agonist drug to facilitate GLP‑1 benefits while simultaneously mitigating muscle loss.

Pre‑clinical · IND‑enabling studies planned

MANF, a therapeutic protein biologic candidate in pre-clinical development

MANF (TolloBio)

Pre‑clinical following BLA pathway

A therapeutic protein biologic candidate that supports protein folding in the endoplasmic reticulum and helps reverse cellular senescence, studied across neurodegenerative, ocular and cardiometabolic disease. Therapeutic indications include long COVID induced vision loss, long COVID, Wolfram Syndrome and Retinitis Pigmentosa.

Pre‑clinical · IND‑enabling studies planned · License from Amarantus Bioscience not yet executed

Forzet, Tollovid and Galectovid are not drugs. They have not been evaluated by the FDA and are not intended to diagnose, treat, cure or prevent any disease. Tolloglutide is an investigational candidate and has not been approved by any regulator. MANF is an investigational candidate and has not been approved by any regulator.

Health Lives Here

Technology‑Enabled Support

The Health Lives Here consumer app pulls medical history, diagnostics and prescription data into one place, includes wearables data, then connects the user to a prescribing physician through a white label integration with MD Integrations.

It is designed so the same clinician who prescribes a GLP‑1, treats acute viral infection or helps patients manage their long COVID can also manage the patient’s use of prescription drugs and Forzet, Galectovid and Tollovid, integrating a medical food or supplement purchase into the physician’s supervised care plan. The app is in pre launch optimization and is targeted to go live in September 2026.

1

NFL Alumni Health partnership

Former players act as brand ambassadors under a profit sharing arrangement.

2

Clinician in the loop

Telemedicine is delivered through MD Integrations, which maintains its own state level licensure and provider credentialing.

3

Products attached to care

Forzet, Tollovid and Galectovid are surfaced inside the care plan rather than sold in isolation.

Partner and counterparty marks are shown for identification purposes only and do not imply any endorsement of this communication.

Route to Market

Distribution across consumer, clinician and pharmacy channels.

The app

Health Lives Here connects patients to a prescribing physician who can manage GLP‑1 therapy, acute viral infections and long COVID symptoms alongside the product.

Direct to consumer

Sold online through the company’s store at Tollohealth.shop.

Physicians

Educating physicians and health practitioners who manage weight loss, acute viral infection and long COVID patients.

Retail pharmacy

A partnership agreement with Corexa Pharmacy, intended as the primary US direct‑to‑consumer pharmacy online strategy so patients can get their drugs, medical foods and supplements in one place.

Wholesale B2B

Wellgistics Distribution and its network of more than 6,500 independent pharmacies.

Brand ambassadors

NFL Alumni Health provides reach into a health‑motivated audience through former players and their communities.

Related party disclosure

Corexa Pharmacy and Wellgistics Distribution are subsidiaries of Corexa Health, which is itself a subsidiary of DataMeds AI, Inc. (formerly Wellgistics Health, Inc.). DataMeds AI is expected to acquire a controlling interest in Tollo Health, and Tollo Health’s CEO currently serves as Interim Co‑CEO of DataMeds AI. These distribution arrangements are therefore related party transactions and may not have been negotiated on a purely arm’s length basis.

Planned Offering

What the company is contemplating

These terms are preliminary, have not been finalized, and are shown so you can decide whether this is worth your attention. They may change in any respect, and no Form C has been filed with the SEC.

Security

SAFESimple Agreement for Future Equity, post money

Valuation cap

$150,000,000With a 20% discount rate

Target raise

$5,000Maximum $1,235,000

Minimum investment

$500Per investor

Intended use of proceeds

R&D and marketingSplit between Forzet commercialization and Tollovid clinical data

Intermediary

Mr. CrowdKsdaq, Inc. dba Mr. Crowd, SEC registered funding portal and FINRA member

Proceeds from the planned offering are intended to fund more formal clinical studies of Tollovid, alone and in combination with Galectovid, in long COVID.

The target offering amount is nominal and is set at the level the company must reach for the offering to close. It is not an indication of the capital the company needs to execute its business plan. A SAFE is neither equity nor debt. It converts into equity only if a triggering event occurs, it carries no voting rights, and it may never convert. Any offering would be made only through a Form C filed with the SEC and conducted on the Mr. Crowd portal.

The Road Ahead

A commercial year, not a research year

Tollo Health has moved from formulation to launch. The next twelve months are about proving the products sell, and generating the clinical data that would let the company say more about what they do.

A transaction has been publicly disclosed under which DataMeds AI, Inc. is expected to acquire a controlling interest in the company as part of a broader arrangement involving Datavault AI, EOS Technology Holdings, Scilex Holdings, HighBridge Advisors and Fortitude Advisors. It remains subject to definitive agreements and there is no assurance it will close on the terms contemplated, or at all.

Dec 2025

Tollovid back on sale

Relaunched under the company’s own license with NLC Viral Defense, LLC.

Now

Testing the waters

Gauging investor interest in a planned Regulation Crowdfunding offering on Mr. Crowd.

Sept 2026

Forzet and Health Lives Here launch

Timed to the Pro Football Hall of Fame Game in Canton, Ohio, with NFL Alumni Health.

Expected 2026

Change of control

DataMeds AI transaction targeted to close, subject to definitive agreements.

Planned

Clinical data and IND

Formal Tollovid studies in long COVID, and IND‑enabling work for MANF within roughly 18 months.

Leadership

Operators who have run this play before

The team combines biopharma company building, global life sciences licensing and specialty pharmacy operations.

Gerald Commissiong

Chief Executive Officer

18 years in biopharma. Chief Business Officer at OS Therapies. Former co founder of Amarantus Bioscience and former CEO of Todos Medical. Has raised more than $150 million for scientific development programs and commercial healthcare companies. B.Sc. in Management Science & Engineering, Stanford University.

Daniel Hirsch

Chief Financial Officer

Managing Partner of First Line Capital since 2002 and former CFO and director of Todos Medical. B.A. in Economics, Yeshiva University; M.P.H., New School for Social Research.

Nikul Panchal, RPh

Head of Operations

Board certified nuclear pharmacist licensed in five states, with 25 years leading specialty, retail and radio‑pharmacy operations. Chief Pharmacy Officer at Wellgistics.

Indicate Your Interest

Get the first look at the Tollo Health offering

Register to tell the company you would like to hear more, and be notified the moment the offering officially opens. It takes under a minute and commits you to nothing.

No payment now, non‑binding
Notified first when it opens
Withdraw at any time

No commitment · No payment · You can withdraw your interest at any time.

About this communication

Tollo Health, LLC is “testing the waters” to gauge investor interest in an offering under Regulation Crowdfunding. No money or other consideration is being solicited, and if sent, it will not be accepted. No offer to buy securities will be accepted, and no part of the purchase price will be received, until a Form C offering statement is filed with the SEC and only through an approved intermediary platform. An indication of interest involves no obligation or commitment of any kind. Any person’s indication of interest may be withdrawn at any time before securities are sold.

About Tollo Health

Tollo Health, LLC is a Delaware limited liability healthcare company organized in August 2024 and headquartered in Tampa, Florida that develops and commercializes nature‑based therapeutics, including Forzet, Tollovid and Galectovid, through its TolloMeds, LLC subsidiary. Tollo Health also intends to offer telemedicine services via its Health Lives Here telehealth platform in subsidiary TolloCare, LLC (dba Health Lives Here). The Company is also incubating the development of biopharmaceutical drugs through its TolloBio, LLC subsidiary.

Corexa Health Pharmacy, a subsidiary of DataMeds AI, Inc., distributes select Tollo Health products under a wholesale distribution arrangement.

Risk and forward looking statements

Investing in a private company is highly speculative and you should be prepared to lose your entire investment. The company has a limited operating history, minimal revenue to date, and products that have not yet launched commercially. Its management team has limited experience operating this particular company together, and its internal controls and financial reporting systems are still being developed.

This page contains forward looking statements, including statements using words such as “anticipate”, “expect”, “intend”, “plan”, “may” and “will”. Actual results may differ materially. Product launch dates, distribution arrangements, clinical study plans, the anticipated MANF license from Amarantus Bioscience Holdings, and the anticipated change of control transaction with DataMeds AI are all subject to conditions outside the company’s control and may be delayed, changed or abandoned. Several counterparties named on this page are related parties whose transactions with the company may not reflect arm’s length terms.

Statements on this page speak only as of the date shown to you and, except as required by law, the company disclaims any obligation to update them. Market size figures are third party estimates and are not projections of the company’s revenue.

Product statements

Forzet, Tollovid, Galectovid, Galectovid (MCAS) and Chondrovid have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure or prevent any disease. Medical foods are intended for use under the supervision of a physician. Tolloglutide and MANF are investigational product candidates and their safety and efficacy have not been established.

Food as medicine, built to pharmaceutical standards